PepEvolutionAOD-9604
A modified HGH fragment (176-191) for fat loss, the only one in its class to complete a phase-2b trial, which failed its primary endpoint.
Verdict, C · Emerging / Mixed
The rare gray-market peptide that actually completed a human RCT, and failed. A benign safety profile is not enough to offset a failed phase-2b endpoint. D-grade; gray-market versions add sourcing uncertainty on top of the weak efficacy case.
Overview
AOD-9604 is a modified form of HGH fragment 176-191 studied by Metabolic Pharmaceuticals (Australia) through a phase-2b obesity trial (METAOD006/METAOD008) that failed to demonstrate statistically significant weight loss vs placebo at 24 weeks. The compound has a benign safety profile, and gray-market availability is moderate. The failed trial is the defining data point: meaningful human evidence was sought and not found.
PepScore Breakdown, the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version?, our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI, see methodology.
Want a clinical path?
Talk to a licensed provider about AOD-9604 and whether it's appropriate for your situation.
Talk to a Provider ↗Telehealth. Not medical advice, for educational purposes.
Get the PepEvolution Dispatch
Monthly COA findings, vendor changes, and new grades. Research/educational only, no spam.
Educational only, not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links, this never affects grades. Consult a licensed healthcare provider before using any compound.